Connect with us

Acquisition

MedAlliance, a Pioneering Medical Device Startup, acquired by Cordis of USA in a Landmark USD 1.135 Billion Deal

Published

on

medalliance

MedAlliance, the visionary Swiss-based medical technology company, is delighted to announce the successful acquisition by Cordis, a transaction valued at USD 1.135 billion (Rs. ~ 10,000 Crores). This union represents a remarkable milestone in the realm of medical innovation, furthering our shared commitment to addressing global healthcare challenges.

Amit Bohora, an early MedAlliance partner, who diligently helped steer this transaction from its inception to its conclusion, hails this acquisition as a testament to our unwavering dedication to serving patient benefit and humanity’s medical needs.

“MedAlliance, a pioneer in drug device combinations, has harnessed innovation to provide a ground-breaking solution – the patented Sirolimus Drug Eluting Balloon, Selution SLR. This innovation ensures the effective delivery of the necessary medication while leaving nothing behind, revolutionizing the landscape of stentless PCI angioplasty. With Cordis, a vanguard in the field that introduced CYPHER Drug-Eluting Stents in 1999, championing this innovation is the logical progression. MedAlliance’s years of research, coupled with ongoing and successful clinical studies in Asia, Europe and the United States, has resulted in CE mark approvals and four breakthrough US FDA IDE indications.” cites Mr. Amit Bohora.

“Amit has been a key contributor since foundation to MedAlliance’s business and he has been an intricate part of our success, advising management and leading the worldwide commercial team, as well as the Asian clinical team. He was responsible for several important studies, including leading the Indian coronary study used for CE mark approval and has assisted in fund raising and led the commercial transition of MedAlliance integration into Cordis.” said Mr. Jeffrey Jump, Founder, Chairman and CEO of MedAlliance.

At the core of this achievement lies MedAlliance’s ground-breaking creation – the Sirolimus Drug-Eluting Balloon (DEB), renowned as Selution SLR. This transformative technology is poised to impact the lives of millions around the world.

“I have known Amit for over two decades, he has played an important role in creating and bringing to market an innovative technology that has a potential to serve millions of patients in this exciting era of Stentless Angioplasty. With first-hand experience coupled with impressive clinical outcomes, SELUTION SLR in India, Japan and Europe. This technology has the distinct opportunity to change the treatment paradigm for patients suffering from Cardiovascular and Peripheral Disease” commented Dr. Praveen Chandra– Chairman – Interventional & Structural Heart Cardiology, Medanta Hospital, India.

MedAlliance, with its manufacturing facility in the United States and cutting-edge research and development centers in Switzerland and Singapore, specializes in pioneering technology and the commercialization of advanced drug-device combination products, initially tailored for coronary and peripheral artery diseases. Currently, more than 1,700 patients, out of a planned 3,326, have been enrolled in a ground-breaking Coronary randomized controlled study, designed to compare SELUTION SLR with any limus Drug-Eluting Stent (DES), with the aim of demonstrating the superiority of SELUTION SLR DEB over DES. SELUTION DeNovo, the largest DEB study ever initiated, holds the potential to redefine medical practice. Furthermore, following successful in human trials in Asia, this ground-breaking product is being embraced by distinguished cardiologists and esteemed specialty hospitals in India and rest of the world. 40,000 patients worldwide have benefited from this technology.

“With over two decades of experience in healthcare and medical technology, spanning strategy, research, and business, Mr. Amit Bohora has been instrumental in vision of making this transformative technology accessible worldwide, as I am sure he will do for many companies in the future”, said Jeffrey B. Jump, founder, Chairman and CEO of MedAlliance.

“With over 100 million diabetic patients, India stands at the threshold of a medical technology revolution, a trillion-dollar opportunity. The nation’s burgeoning healthcare sector not only fuels economic growth but also benefits from a positive funding environment. In a country boasting one of the world’s largest cardiovascular patient population, this is the next frontier of growth in healthcare. The Indian medical device industry, already valued at 90 Thousand Crore Rupees (11 Billion USD), is projected to surge to 3.6 Lakh Crore Rupees (44 Billion USD) by 2030, underscoring the immense potential and vitality of the healthcare landscape in India.” added Mr. Amit Bohora.

The acquisition of MedAlliance serves as an indomitable reminder that extraordinary products, when aligned with the noble mission of enhancing human lives, should be made universally available. Cordis will play a pivotal role in the marketing, distribution, and global accessibility of this revolutionary Drug-Eluting Balloon. As the company continues its journey toward securing US FDA Investigational Device Exemption (IDE) approvals, it stands on the precipice of delivering profound impact to millions of lives in the immediate future.

Acquisition

Höegh Evi: Acquisition of FSRU Independence by KN Energiés completed

Published

on

HAMILTON, Bermuda and KLAIPĖDA, Lithuania, Dec. 6, 2024 — Höegh Evi, a global leader in marine energy infrastructure solutions, has officially transferred ownership of the floating storage and regasification unit (FSRU) Independence to KN Energies and the country of Lithuania, marking a significant milestone in the nation’s energy development.

The Independence was commissioned by the Republic of Lithuania in 2014 and was engineered with regasification capacity to fully meet the country’s gas needs. The agreement between Höegh Evi and the Republic of Lithuania provided for the option to acquire and own the FSRU by the end of 2024. The transfer of ownership to the state underscores Lithuania’s long-term commitment to maintaining this critical asset. 

“Klaipėda’s LNG terminal stands as a powerful symbol of Lithuania’s political resolve, determination, and commitment to achieving energy independence. It has played a pivotal role in reshaping the country’s energy landscape and enhancing regional energy security, opening up new opportunities for diversification. The terminal represents Lithuania’s frontline in the ongoing pursuit of energy independence, and we take immense pride in the fact that the Lithuanian flag will now proudly fly over it,” said the President of the Republic of Lithuania, Gitanas Nausėda.

Independence: a symbol of success in energy security     

Under Höegh Evi’s management, the Independence has supplied nearly 16 billion cubic meters of natural gas to Lithuania and surrounding countries. It has maintained a strong operational record, with close to 500 ship-to-ship operations and no safety incidents.

“The acquisition of the FSRU Independence by Lithuania is a proud moment for Höegh Evi. A decade ago, Lithuania’s vision to leverage marine infrastructure for energy security set a powerful example. The Independence is now a cornerstone of the region’s critical energy infrastructure. Höegh Evi is honoured to continue working with KN Energiés to provide Lithuania and its neighbours with a reliable supply of natural gas,” said Erik Nyheim, President & CEO of Höegh Evi. 

Höegh Evi to continue as technical operator of FSRU Independence

After the transfer of ownership, Höegh Evi will continue to provide KN Energiés with technical and operational management of the vessel.   

“While the ownership of Independence is changing, our decade-long partnership with Höegh Evi remains strong. Hoegh LNG Klaipėda, part of the Höegh Evi group, will continue to provide technical operation and maintenance of the FSRU for the next five years, with an option to extend this cooperation for an additional five years. Over the years, the company has proven to be a reliable and trusted partner, and we are pleased to see this mutually beneficial and growth-oriented partnership continue,” said Darius Šilenskis, CEO of KN Energies.

Continue Reading

Acquisition

Lockheed Martin to Acquire Terran Orbital

Published

on

Strategic Acquisition Reinforces Lockheed Martin’s Commitment to Expanding Advanced Satellite Manufacturing and Responsive Space Capabilities

BETHESDA, Md., Aug. 15, 2024 — Lockheed Martin [NYSE: LMT] today announced the signing of a definitive agreement to acquire Terran Orbital [NYSE: LLAP], a global leader of satellite-based solutions primarily supporting the aerospace and defense industries.

Terran Orbital brings a high throughput, robotic manufacturing capacity and high-performing modular space vehicle designs. Combined with Lockheed Martin’s record of performance and innovation, this transaction will usher in an even broader range of capabilities and value for customers. Lockheed Martin uses Terran Orbital’s satellites for its work, most notably with the Space Development Agency’s Transport and Tracking Layer programs, and in several of its self-funded technology demonstrations.

“We’ve worked with Terran Orbital for more than seven years on a variety of successful missions,” said Robert Lightfoot, president, Lockheed Martin Space. “Their capabilities, talent and business momentum align with Lockheed Martin Space’s strategic plans – and we’re looking forward to welcoming them to our team. Our customers require advanced technology and even faster product development, and that’s what we can achieve together.”

The transaction stands to pave a path for further advancement, as Lockheed Martin continues to invest in technology, people, and capacity to support future customer needs.

“This transaction combines our strengths and expertise,” said Marc Bell, chairman, CEO, and co-founder of Terran Orbital. “This move will open new opportunities for growth and innovation, and we couldn’t be more excited about the future. Access to Lockheed Martin’s incredible engineers and world class facilities will only accelerate our business plan to provide low-cost, high-value solutions to our ever-growing customer base.”

Transaction Details

The enterprise value of the transaction is approximately $450 million. Lockheed Martin will acquire Terran Orbital for $0.25 in cash for each outstanding share of common stock and retire its existing debt. This transaction also provides for Lockheed Martin and other current Terran Orbital creditors establishing a new, $30 million working capital facility that has been put in place as of signing.

The transaction is expected to close in fourth quarter of 2024 and is subject to the satisfaction of customary closing conditions, including regulatory and Terran Orbital stockholder approvals. Upon closing, Terran Orbital will remain a commercial merchant supplier to industry.

Proven Spacecraft Portfolio and Technology

Terran Orbital has a track record of supporting more than 80 missions over the past decade for government and commercial customers with complex mission requirements, from low earth orbit to the Moon and beyond. As of today, Lockheed Martin is Terran Orbital’s largest customer. This longstanding working relationship between the companies underpins a strong cultural alignment and ability to recognize synergies between the two businesses.

Terran Orbital joined the Lockheed Martin Ventures (LM Ventures) portfolio – a fund that makes investments in technology innovations to drive growth in existing, adjacent and new segments for the company – with an initial investment in 2017. LM Ventures has since made two additional investments in Terran Orbital in 2020 and 2022. This marks the first LM Ventures company that Lockheed Martin has sought to acquire since founding the fund in 2007.

About Lockheed Martin

Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready.

About Terran Orbital

Terran Orbital is a leading manufacturer of satellite products primarily serving the aerospace and defense industries. Terran Orbital provides end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and on-orbit support to meet the needs of the most demanding military, civil, and commercial customers.

Continue Reading

Acquisition

Arieli EL to Acquires a 59.1% Stake in Elron Ventures, a Leading Cybersecurity and B2B Software Holding Company, for $53.2M

Published

on

The acquisition underscores the continued strength of the Israeli cyber and B2B software, where cyber exits accounted for 51% of total tech transactions in 2023. Lisya Bahar-Manoah is leading the acquisition and has joined Arieli EL as Managing Partner.

NEW YORK and TEL AVIV, Israel, July 22, 2024 — Arieli EL, part of the Arieli group of companies, has today announced the acquisition of a 59.1% stake in veteran cyber and B2B software holding company Elron Ventures (TASE: ELRN) for $53.2 million from Discount Investment Corporation Ltd. This acquisition highlights the significant market opportunities within the Israeli ecosystem, especially in cybersecurity and defense. Lisya Bahar-Manoah, Managing Partner at Arieli EL, is leading the acquisition of Elron Ventures (Elron).

Gartner forecasts that security and risk management spending will reach over $200 billion globally in 2024, representing a 14.3% year-over-year growth. This trend demonstrates the growing importance of cybersecurity, a sector where Israel, home to over 500 cybersecurity companies, is regarded as a global leader.

“The gap between real-time cyber solutions and evolving cyber threats is a critical challenge,” said Lisya Bahar-Manoah, Managing Partner at Arieli EL. “In 2023, there were more than 300 million victims of cybercrime globally, with data breaches rising by 78% in the US alone. Israeli cybersecurity exits in 2023 grew by 65% totalling $7.1 billion, and we see this trajectory only gathering pace in 2024 as demonstrated by reports of Google’s acquisition of Wiz for $23 billion. We are excited to be partnering with Elron’s team as well as Elron’s joint venture with Rafael Advanced Defense Systems (Rafael) to further contribute to this sector and continue building innovative solutions for sustained growth.”

Elron Ventures has over $250 million in assets under management (AUM) and its portfolio includes over 19 companies across the cybersecurity, B2B Software, and health-tech spaces. Since 2010, Elron’s portfolio has had 15 exits, totaling $2.2B. Notable portfolio companies include: Cynerio, a healthcare cybersecurity company, ensures patient safety and data protection by securing the connected medical device ecosystem; Cybersixgill, developing automated threat intelligence solutions across the clear, deep, and dark web; Cyvers, offering a real-time platform for detecting and mitigating cyber attacks on cryptocurrency and digital assets; IRONSCALES, an automated phishing prevention, detection & response platform; Sayata, automating insurance company processes; Red Access, providing the first agentless platform to secure all browsing activities of corporate employees on any browser, web app or cloud service and Scribe Security, providing a comprehensive solution to secure software supply chains.

“We are excited to have the opportunity to combine our joint experience and know-how in nurturing Israeli tech ventures throughout all stages of growth with Arieli’s vast global network to provide the platform for our portfolio’s success,” said Dan Hoz, Chairman of the Elron Venture’s board.

About Arieli EL

Arieli EL, part of the Arieli group of companies, addresses global challenges with a forward-thinking investment strategy. Arieli EL has deep roots in the global family office space, specializing in High-tech and Healthcare investments. Arieli EL strives to provide family offices and institutional investors with access to unique opportunities while providing portfolio companies access to our global network.

About Arieli Capital

Arieli Capital (Arieli) is a multifaceted global investment firm that is an active investor and partner in the next generation of technology companies. Arieli Capital continuously strives to identify and support companies creating real impact while keeping financial returns as the primary objective. Arieli is a recognized global leader in innovation, creating  and operating  programs across governmental, academic and corporate partnerships.

About Elron Ventures

Elron Ventures is a leading early-stage investor committed to turning promising ideas into global industry leaders, with a proven track record of investments and successful M&As worldwide. Elron invests in cyber security and B2B software.

Continue Reading

Trending

Subscribe to our Free Newsletter

Get Business and Marketing Insights from Experts, only onTimes of Startups!

Your Information will never be shared with any third party